Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840129 | 1.00 | NLRP3 (0.39) | NLRP3ALDH1A1EPHX1NPC1TRPA1 | |
| SCHEMBL16366 | 0.87 | — | — | |
| SCHEMBL232996 | 0.85 | — | — | |
| SCHEMBL26352813 | 0.81 | NLRP3 (0.39) | NLRP3TRPA1 | |
| SCHEMBL17208385 | 0.80 | ALDH1A1 (0.35) | ALDH1A1EPHX1NPC1MAPTPOLB | |
| SCHEMBL7737609 | 0.80 | ALDH1A1 (0.35) | ALDH1A1EPHX1NPC1MAPTPOLB | |
| SCHEMBL15199188 | 0.80 | ALDH1A1 (0.35) | ALDH1A1EPHX1NPC1MAPTPOLB | |
| SCHEMBL9912093 | 0.80 | NLRP3 (0.42) | NLRP3TRPA1 | |
| SCHEMBL14981377 | 0.78 | NLRP3 (0.41) | NLRP3 | |
| SCHEMBL21834039 | 0.78 | LMNA (0.48) | NLRP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563742-B2 | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | VTVX HOLDINGS I LLC | 2010-03-04 | — | — | US | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | MC4R, MC3R, MC5R | NLRP3 237/4885ALDH1A1 2694/4885EPHX1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.